OUR MISSION
Our mission is to provide new healthcare options and innovative medicines for underserved communities worldwide.
OUR ORGANISATION
Atticus Medical is developing new treatments for diseases that have global impact. The company was founded in December 2019 by Medicines Development for Global Health (Melbourne) and the Global Health Investment Fund (New York).
Our strategy is to leverage financial returns from high-income pharmaceutical markets to deliver benefits to both shareholders and patients in both high- and low-income countries.
Our lead product, moxidectin, is approved by the US FDA for the treatment of river blindness (onchocerciasis). Atticus holds exclusive rights to moxidectin for multiple indications, including scabies and head lice, and we are actively developing it for these conditions, which have significant global markets.
COMPANY MILESTONES
Company founded
Seed capital investment by founders MDGH and GHIF
Key licence to moxidectin IP received
Proof-of-concept clinical trial of AM-2 for scabies completed
Phase 2b trial of AM-2 for scabies initiated
